Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2015Molecular CancerOpen Access

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRosalba CamiciaPfizer (United Kingdom)HWHans Christian WinklerETH ZurichPHPaul O. HassaEuropean Molecular Biology Laboratory

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Camicia et al. (2015) studied this question.

synapsesocial.com/papers/6a10558957bfcc72645fed9ehttps://doi.org/10.1186/s12943-015-0474-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PKCβ regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA12005 · 165 citations
  2. 2Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide2011 · 606 citations
  3. 3The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications2011 · 2,016 citations
  4. 4Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study2010 · 158 citations